CL2007001886A1 - Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros. - Google Patents

Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.

Info

Publication number
CL2007001886A1
CL2007001886A1 CL2007001886A CL2007001886A CL2007001886A1 CL 2007001886 A1 CL2007001886 A1 CL 2007001886A1 CL 2007001886 A CL2007001886 A CL 2007001886A CL 2007001886 A CL2007001886 A CL 2007001886A CL 2007001886 A1 CL2007001886 A1 CL 2007001886A1
Authority
CL
Chile
Prior art keywords
ureas
pyrrolidine
hypertension
piperidine
diabetes
Prior art date
Application number
CL2007001886A
Other languages
English (en)
Inventor
Alain Braun
Claudie Namane
Patrick Mougenot
Eric Nicolai
Stefan Gussregen
Francois Pacquet
Christophe Philippo
Ol Venier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0605786A external-priority patent/FR2902790A1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2007001886A1 publication Critical patent/CL2007001886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de obesidad, diabetes, resistencia a la insulina, síndrome de Cushing, hipertensión, aterosclerosis, demencia, glaucomas, osteoporosis.
CL2007001886A 2006-06-27 2007-06-26 Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros. CL2007001886A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605786A FR2902790A1 (fr) 2006-06-27 2006-06-27 Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique
FR0611239 2006-12-22

Publications (1)

Publication Number Publication Date
CL2007001886A1 true CL2007001886A1 (es) 2009-11-10

Family

ID=38692075

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001886A CL2007001886A1 (es) 2006-06-27 2007-06-26 Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.

Country Status (16)

Country Link
US (1) US7947834B2 (es)
EP (1) EP2044057A2 (es)
JP (1) JP2009541463A (es)
KR (1) KR20090021192A (es)
AR (1) AR061643A1 (es)
AU (1) AU2007264791A1 (es)
BR (1) BRPI0713042A2 (es)
CA (1) CA2652852A1 (es)
CL (1) CL2007001886A1 (es)
IL (1) IL195820A0 (es)
MX (1) MX2008016563A (es)
PE (1) PE20080212A1 (es)
RU (1) RU2009102527A (es)
TW (1) TW200811158A (es)
UY (1) UY30448A1 (es)
WO (1) WO2008000950A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
FR2948369B1 (fr) * 2009-07-27 2013-04-12 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR2948370B1 (fr) * 2009-07-27 2013-04-05 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2727169C2 (ru) 2013-11-18 2020-07-21 Форма Терапеутикс Инк. Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
JP2024516455A (ja) * 2021-05-07 2024-04-15 オルガノン・アール・アンド・ディ・フィンランド・リミテッド 新規ヘテロ環式化合物、組成物、その製造および使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130795B1 (en) 1983-07-05 1988-11-23 Pfizer Inc. Carboxylic acid derivatives useful for inhibiting the degradation of cartilage
US6369057B1 (en) * 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
EP0590022A1 (en) * 1991-06-14 1994-04-06 PHARMACIA & UPJOHN COMPANY IMIDAZO 1,5-a]QUINOXALINES
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
ITMI20012060A1 (it) * 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
US20050256159A1 (en) * 2002-10-11 2005-11-17 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
GB0325745D0 (en) * 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GEP20125565B (en) * 2004-11-10 2012-07-10 Incyte Corp Lactam compounds and their pharmaceutical use
CN101103016A (zh) * 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
JP5140577B2 (ja) * 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
CA2610172A1 (en) * 2005-06-08 2006-12-14 Japan Tobacco Inc. Heterocyclic compound

Also Published As

Publication number Publication date
TW200811158A (en) 2008-03-01
PE20080212A1 (es) 2008-04-25
WO2008000950A2 (fr) 2008-01-03
RU2009102527A (ru) 2010-08-10
UY30448A1 (es) 2008-01-31
US7947834B2 (en) 2011-05-24
AU2007264791A1 (en) 2008-01-03
US20090176775A1 (en) 2009-07-09
CA2652852A1 (fr) 2008-01-03
JP2009541463A (ja) 2009-11-26
EP2044057A2 (fr) 2009-04-08
WO2008000950A3 (fr) 2008-02-14
BRPI0713042A2 (pt) 2013-01-08
KR20090021192A (ko) 2009-02-27
IL195820A0 (en) 2009-09-01
AR061643A1 (es) 2008-09-10
MX2008016563A (es) 2009-03-02

Similar Documents

Publication Publication Date Title
CL2007001886A1 (es) Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
CL2008002871A1 (es) Compuestos derivados de oxadiazol-bencimidazol; composicion farmaceutica que los contiene y su uso como inhibidores de dgt1 para el tratamiento de la tolerancia deteriorada a la glucosa, diabetes tipo 2 y obesidad.
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
SG165315A1 (en) Alpha2c adrenoreceptor agonists
CL2007003614A1 (es) Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
CL2008001197A1 (es) Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras.
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2011000501A1 (es) Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras.
CL2008002916A1 (es) Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros.
CL2007003733A1 (es) Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2007001885A1 (es) Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis.
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
JO3042B1 (ar) مشتقات السيكلوبيرازول-لاكتام كمثبطات لل 11-بيتا-هيدروكسي ستيرويد داي هيدروجينيز 1
IL195030A (en) IV dpp inhibitor assemblies
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CL2007001022A1 (es) Compuestos derivados de 1h-indol-2-carboxamida; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de los receptores de h3 tal como obesidad, diabetes tipo ii y
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.